BoB@JPM: Kasper Roet, Ph.D., QurAlis

Business Of Biotech

We love to hear from our listeners. Send us a message.

Dr. Kasper Roet's hands-on work at the Dutch Brain Bank informed his leadership at the biotech QurAlis, where three clinical programs targeting specific genetic mechanisms in ALS are now underway. On this episode of the Business of Biotech, Life Science Leader's Ben Comer joins to co-host a conversation with Dr. Roet that goes deep on his company's genetic medicine approach to ALS, and even deeper into his opinions on, and growing influence over, the regulatory environment. Roet says that as the FDA's conservative approach to genetic medicines has pushed clinical trials overseas, he's been inspired to form and lead a consortium of 11-and-growing biotechs seeking regulatory reform through organized meetings and lobbying efforts. Join us for this latest of our BoB@JPM series from San Francisco.
The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. Dr. Root's Path From IT to Neuroscience (00:00:00)

2. Hands-On Experience at Dutch Brain Bank (00:10:13)

3. Founding Curalis Through Patient-Derived Models (00:18:21)

4. Regulatory Challenges for Genetic Medicines (00:22:05)

5. Clinical Programs and Development Pipeline (00:33:53)

6. The Future of Genetic Medicine for ALS (00:42:26)